ROCK1 and lymphoma: Consistent with previous results in mouse fibroblasts that demonstrated the resistance of ROCK1 NC to caspase-mediated proteolysis (Julian et al., 2021), treatment of lymphoma cells with a combination of the BCL-2-selective inhibitor ABT199 (Souers et al., 2013) and cycloheximide (Chx) to induce apoptosis resulted in protein cleavage of ROCK1 WT but not ROCK1 NC (Fig. 1A).